Durvalumab for advanced mismatch repair-deficient and repair-proficient endometrial cancer
Prof. Yoland Antill
A multicenter nonrandomized phase 2 study in Australia and New Zealand evaluated durvalumab for advanced endometrial cancer in a cohort of patients with mismatch repair-deficient tumors and in a cohort of patients with mismatich repair-proficient tumors. The ORR was 47% in the dMMR cohort and 3% in the pMMR cohort. PFS (panel A) and OS (panel B) were promising in the dMMR cohort.
